« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | pomalidomide |
| Code Name: | CC-4047, Actimid |
| Company: | Celgene |
| FDA Clinical Phase: | 1/2 |
Description:
Pomalidomide (new articles, forum discussions) is an immunomodulatory agent (a drug that affects the immune system) that encourages a patient’s immune system to attack and destroy myeloma cells.| Brand Name: | |
| Generic Name: | |
| Code Name: | CEP-18770 |
| Company: | Cephalon |
| FDA Clinical Phase: | 1/2 |
Description:
CEP-18770 is a boronic-acid based proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Animal studies showed that …
| Brand Name: | |
| Generic Name: | |
| Code Name: | CX-4945 |
| Company: | Cylene |
| FDA Clinical Phase: | 1 |
Description:
CX-4945 is an oral anti-cancer agent. It inhibits CK2, an enzyme …
| Brand Name: | Istodax |
| Generic Name: | romidepsin |
| Code Name: | depsipeptide |
| Company: | Celgene |
| FDA Clinical Phase: | 2 |
Description:
Istodax is a bicyclic depsipeptide antibiotic that binds and inhibits an …
| Brand Name: | Genasense |
| Generic Name: | oblimersen |
| Code Name: | G3139 |
| Company: | Genta, Inc. & Aventis |
| FDA Clinical Phase: | 3 |
Description:
Genasense is a type of antisense oligodeoxyribonucleotide. It may kill cancer cells by| Brand Name: | |
| Generic Name: | elotuzumab |
| Code Name: | HuLuc63 |
| Company: | Facet Biotech/Bristol-Myers Squibb |
| FDA Clinical Phase: | 1/2 |
Description:
Elotuzumab (news), a monoclonal antibody, selectively targets glycoproteins that are highly expressed on myeloma cells but not on healthy cells. In the presence …
